Abstract
High frequency stimulation (HFS) of the subthalamic nucleus (STN) is an efficacious symptomatic treatment for Parkinson's disease. We have analysed the genetic status of a series of consecutive parkinsonian patients implanted for STN HFS and compared the outcome of five carrying mutations in the parkin gene with that of the non-parkin group. All patients obtained sustained control of PD symptoms and achieved functional improvement; in the parkin group the UPDRS motor score improved by 56.4%, the levodopa equivalent daily dosage was reduced by 75.5%. Postoperative medications were reduced more in parkin than in non-parkin patients. We confirm that the current inclusion criteria for STN HFS do not exclude patients carrying mutations in the parkin gene; their clinical outcome is comparable to that of the non-parkin group.
Original language | English |
---|---|
Pages (from-to) | 208-211 |
Number of pages | 4 |
Journal | Journal of Neurology |
Volume | 252 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2005 |
Keywords
- Deep brain stimulation
- Neurostimulation
- PARK2
- Parkin disease
- Parkinson's disease
- Subthalamic stimulation
- Surgery
ASJC Scopus subject areas
- Clinical Neurology
- Neurology